ATH434 not checked

Alterity Therapeutics · PBT434

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
Tested for
Multiple System Atrophy
Main trialPhase 2
“This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.”In the company’s words, NCT07729852 on ClinicalTrials.gov
Other names
PBT434

Other drugs for Multiple System Atrophy

All 12 drugs for Multiple System Atrophy

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Enrolling by invitation Jul 2029 Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
Phase 2Completed 28 Nov 2024 Study of ATH434 in Participants with Multiple System Atrophy
Phase 2Completed 26 Feb 2025 A Biomarker Study of ATH434 in Participants With MSA
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ATH434

Following is part of Solo: you see every change to ATH434 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in